Filtered By:
Specialty: Endocrinology
Condition: Diabetes

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 1416 results found since Jan 2013.

Effect of folic acid supplementation on risk of new‐onset diabetes in adults with hypertension in China: Findings from the CSPPT
ConclusionsAmong adults with hypertension with no history of stroke and/or MI in China, folic acid supplementation had no significant effect on the risk of new‐onset diabetes. This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes - October 11, 2015 Category: Endocrinology Authors: Xianhui Qin, Jianping Li, Yan Zhang, Dafang Chen, Binyan Wang, Mingli He, Jia Fu, Genfu Tang, Yefeng Cai, Xiuli Shi, Xin Xu, Fan Fan Hou, Xiaobin Wang, Yong Huo Tags: Original Article Source Type: research

Associations Between Prediabetes, by Three Different Diagnostic Criteria, and Incident CVD Differ in South Asians and Europeans
CONCLUSIONS Associations between prediabetes and CVD differed by prediabetes diagnostic criterion, type of CVD, and ethnicity, with associations being present for overall CVD in Europeans but not South Asians. Substantiation of these findings and investigation of potential explanations are required.
Source: Diabetes Care - November 24, 2015 Category: Endocrinology Authors: Eastwood, S. V.; Tillin, T.; Sattar, N.; Forouhi, N. G.; Hughes, A. D.; Chaturvedi, N. Tags: Epidemiology/Health Services Research Source Type: research

Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone with extrapancreatic effects beyond glycemic control. Here we demonstrate unexpected effects of GIP signaling in the vasculature. GIP induces the expression of the proatherogenic cytokine osteopontin (OPN) in mouse arteries via local release of endothelin-1 and activation of CREB. Infusion of GIP increases plasma OPN concentrations in healthy individuals. Plasma endothelin-1 and OPN concentrations are positively correlated in patients with critical limb ischemia. Fasting GIP concentrations are higher in individuals with a history of cardiovascular di...
Source: Diabetes - December 22, 2015 Category: Endocrinology Authors: Berglund, L. M.; Lyssenko, V.; Ladenvall, C.; Kotova, O.; Edsfeldt, A.; Pilgaard, K.; Alkayyali, S.; Brons, C.; Forsblom, C.; Jonsson, A.; Zetterqvist, A. V.; Nitulescu, M.; McDavitt, C. R.; Duner, P.; Stancakova, A.; Kuusisto, J.; Ahlqvist, E.; Lajer, M. Tags: Complications Source Type: research

Association of the average rate of change in HbA 1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus
Conclusions/interpretation In patients newly started on insulin therapy, rapid and higher HbA1c variability is associated with an increased risk of myocardial infarction, stroke, severe hypoglycaemia and emergency admission.
Source: Diabetologia - January 13, 2016 Category: Endocrinology Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research

Low testosterone - a risk marker rather than a risk factor for type 2 diabetes.
CONCLUSIONS: The observed negative associations of T and SHBG with T2D, but no association to LH and free T, indicates that low T in men who develop T2D is a marker of the disease rather than primary hypogonadism being a causal risk factor. PMID: 27285294 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - June 9, 2016 Category: Endocrinology Authors: Holmboe SA, Jensen TK, Linneberg A, Scheike T, Thuesen BH, Skakkebaek NE, Juul A, Andersson AM Tags: J Clin Endocrinol Metab Source Type: research

Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial
CONCLUSIONS In patients with type 2 diabetes and a recent ACS, the risk of CV death was higher after a postrandomization, nonfatal CV event, particularly heart failure, compared with those who did not experience a CV event. The risk of CV death was similar between alogliptin and placebo.
Source: Diabetes Care - June 20, 2016 Category: Endocrinology Authors: White, W. B.; Kupfer, S.; Zannad, F.; Mehta, C. R.; Wilson, C. A.; Lei, L.; Bakris, G. L.; Nissen, S. E.; Cushman, W. C.; Heller, S. R.; Bergenstal, R. M.; Fleck, P. R.; Cannon, C. P.; for the EXAMINE Investigators Tags: Cardiovascular and Metabolic Risk Source Type: research

Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
ConclusionsAvailable data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
Source: Acta Diabetologica - August 3, 2016 Category: Endocrinology Source Type: research

Association between Carotid Intima ‐Media Thickness and Fasting Blood Glucose level: A Population‐Based Cross‐Sectional Study among Low‐Income Adults in Rural China
ConclusionsThese findings suggest that it is crucial to manage and control traditional risk factors in low‐income populations in China in order to decelerate the recent dramatic increase in stroke incidence and to reduce the burden of stroke.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - December 31, 2016 Category: Endocrinology Authors: Liu Gao, Lingling Bai, Min Shi, Jingxian Ni, Hongyan Lu, Yanan Wu, Jun Tu, Xianjia Ning, Jinghua Wang, Yukun Li Tags: Original Article Source Type: research

Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: A meta-analysis.
CONCLUSION: GLP1RA therapy when compared to placebo reduced all-cause mortality in high cardiovascular risk patients with type 2 diabetes. They did not impact cardiovascular mortality, nonfatal MI, nonfatal stroke, or heart failure hospitalizations. PMID: 28413990 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - April 14, 2017 Category: Endocrinology Authors: Peterson S, Barry A Tags: Curr Diabetes Rev Source Type: research

Hemoglobin Glycation Index Is Associated with Cardiovascular Diseases in People with Impaired Glucose Metabolism.
Conclusions: High HGI was independently associated with overall and individual CVDs. This result suggests that discrepancy between HbA1c and fasting glucose levels can reflect vascular health in subjects with impaired glucose metabolism. PMID: 28541544 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - May 23, 2017 Category: Endocrinology Authors: Ahn CH, Min SH, Lee DW, Oh TJ, Kim KM, Moon JH, Choi SH, Park KS, Jang HC, Ha J, Sherman A, Lim S Tags: J Clin Endocrinol Metab Source Type: research

Annual direct medical costs associated with diabetes ‐related complications in the event year and in subsequent years in Hong Kong
ConclusionsWide variations in direct medical cost in event year and subsequent years across different major complications were observed. Input of these data would be essential for economic evaluations of diabetes management programmes.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - June 21, 2017 Category: Endocrinology Authors: F. Jiao, C. K. H. Wong, S. C. W. Tang, C. S. C. Fung, K. C. B. Tan, S. McGhee, R. Gangwani, C. L. K. Lam Tags: Research Article Source Type: research

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Conclusions/interpretationThere remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in...
Source: Diabetologia - August 2, 2017 Category: Endocrinology Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research